Related references
Note: Only part of the references are listed.Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials
Jill Whitley et al.
TRANSLATIONAL RESEARCH (2022)
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Xiaoying Shen et al.
CELL HOST & MICROBE (2021)
Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19
Gregory D. Sempowski et al.
CELL (2020)
The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
Anna Vaisman-Mentesh et al.
FRONTIERS IN IMMUNOLOGY (2020)
Reporting, Visualization, and Modeling of Immunogenicity Data to Assess Its Impact on Pharmacokinetics, Efficacy, and Safety of Monoclonal Antibodies
Chaitali Passey et al.
AAPS JOURNAL (2018)
Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab
B. Gorovits et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2018)
Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context
Karien Bloem et al.
THERAPEUTIC DRUG MONITORING (2017)
Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points
Viswanath Devanarayan et al.
AAPS JOURNAL (2017)
Venous and Arterial Thromboembolic Events in Adalimumab-Treated Patients With Antiadalimumab Antibodies
L. A. Korswagen et al.
ARTHRITIS AND RHEUMATISM (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Immunogenicity of rituximab in patients with severe pemphigus
Enno Schmidt et al.
CLINICAL IMMUNOLOGY (2009)
Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies
Rafael Ponce et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2009)
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
Eugen Koren et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products
Gopi Shankar et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
Gopi Shankar et al.
NATURE BIOTECHNOLOGY (2007)
Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate
Harvey J. Motulsky et al.
BMC BIOINFORMATICS (2006)
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products
AR Mire-Sluis et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
How biotinylation can interfere with recognition: a surface plasmon resonance study of peptide-antibody interactions
JC Peter et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
Share Paper
